deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02178436

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer

Sponsor: Mohammed Najeeb Al Hallak

Conditions Acinar Cell Adenocarcinoma of the Pancreas Duct Cell Adenocarcinoma of the Pancreas Stage IV Pancreatic Cancer
Interventions Laboratory Biomarker Analysis Nab paclitaxel Pharmacological Study Selinexor gemcitabine hydrochloride
Updated 14 times since 2017 Last updated: Nov 5, 2023 Started: Oct 31, 2014 Primary completion: Nov 27, 2021 Completion: Apr 5, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Acinar Cell Adenocarcinoma of the Pancreas and Duct Cell Adenocarcinoma of the Pancreas, this trial is completed. The trial is conducted by Mohammed Najeeb Al Hallak and has accumulated 14 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~May 2018 · 8 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~May 2020 · 23 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Dec 2023 · 21 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Suspended → Completed

  4. Mar 2022 — Dec 2023 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  5. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Unknown Status → Recruiting

  2. May 2020 — Oct 2020 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  3. Jun 2018 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Suspended → Active Not Recruiting

  5. Sep 2017 — May 2018 [monthly]

    Suspended PHASE1_PHASE2

  6. Aug 2017 — Sep 2017 [monthly]

    Suspended PHASE1_PHASE2

  7. May 2017 — Aug 2017 [monthly]

    Suspended PHASE1_PHASE2

  8. Feb 2017 — May 2017 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mohammed Najeeb Al Hallak
Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations